Clinical trial NCT05197959: Treatment of Complex Regional Pain Syndrome
Official title: The Feasibility of rTMS and Sensorimotor Training Task for the Treatment of Complex Regional Pain Syndrome: A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Complex Regional Pain Syndrome
Keywords: repetitive transcranial magnetic stimulation
sensorimotor training
complex regional pain syndrome
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: St. Joseph's Healthcare Hamilton
First posted: 2022-01-20
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will investigate the feasibility of using repetitive transcranial magnetic stimulation (rTMS) and a sensorimotor training task to treat symptoms of pain in patients with complex regional pain syndrome (CRPS). rTMS is a non-invasive technique that involves delivering magnetic pulses in rapid succession over the area of the brain that controls movement. The sensorimotor training task involves non-invasive nerve stimulation used to cue a participant to complete motor actions. The purpose of this study is to determine whether recruitment is feasible in this patient population and patients maintain adherence to the intervention. In addition, the investigators want to determine whether rTMS combined with sensorimotor training is an effective intervention to alleviate symptoms of pain in patients with CRPS.

Detailed description: Background: Complex regional pain syndrome (CRPS) is a chronic pain condition characterized by a constellation of sensory, motor and autonomic dysfunction (Gierthmühlen et al., 2014). CRPS can be a debilitating disorder that drastically impacts quality of life. There are two types of CRPS; type 1 in which there is no identifiable nerve injury but occurs after a known noxious event and commonly involves immobilization, and type 2 in which there is a distinct nerve injury. There are challenges in the diagnosis of CRPS and presently the Budapest criteria are modified for the relevant context of research or practice. For this study the investigators plan to use the Budapest modified research criteria as suggested (Harden et al., 2013). CRPS differs from other chronic pain conditions; neuropathic-such as radicular pain or postherpetic neuralgia, or generalized non-specific pain conditions-such as fibromyalgia; in that, pain is associated with obvious and distinct alterations in sensory processing, sympathetic nervous involvement, and motor dysfunction. Limited treatment options for these individuals currently exist, and guidelines are based on expert consensus (Goebel et al, 2019). Existing knowledge suggests that continued physiotherapy with supportive pain control and psychological treatment is the most important strategy to manage CRPS (Goebel et al, 2019).

Repetitive transcranial magnetic stimulation (rTMS) offers a potential opportunity to noninvasively treat pain in patients with CRPS. Some studies have illustrated the analgesic effects of rTMS in patients with CRPS. Gaertner et al. (2018) delivered 10 Hz stimulation to the motor cortex in patients with CRPS. Patients were able to choose between one (n= 6) or five (n= 15) sessions of treatment. A significant reduction in pain was demonstrated in both groups one week following the last treatment session. There were no group differences in changes in pain. Two patients from each group maintained a \>50% reduction in pain relief beyond 6 weeks post treatment. Further, Piceralli et al. (2010) observed a reduction in pain following 10 sessions of 10 Hz rTMS applied to the motor cortex in a group of 12 patients with CRPS. Additionally, Pleger et al. (2004) found that one session of rTMS applied to the motor cortex was sufficient to cause pain relief, however the duration of relief was experienced for only 45 minutes after stimulation. rTMS has been also used in other chronic pain conditions such as neuropathic pain (NP). Sham controlled studies have demonstrated the analgesic effects of rTMS applied to the primary motor cortex on NP symptoms in patients with spinal cord injury (Defrin et al., 2007; Jette et al., 2013; Yilmaz et al., 2014; Sun et al., 2019). These latter effects occur immediately following treatment (Jette et al., 2013) and persist up to six-weeks post-treatment (Yilmaz et al., 2014).

Although the chronic pain condition may vary, analgesic effects of rTMS are suggested to be a result of modulation of nociceptive inhibitory circuits from stimulation of the motor cortex (Lefaucheur et al., 2008; Nizard et al., 2012). This stimulation may cause changes in glutamatergic or GABAergic neurotransmitter pathways leading to a suppression of pain sensation (Lefaucheur et al., 2008; Ciampi De Andrade et al., 2014). Additionally, rTMS facilities neuroplasticity and the retraining of cortical circuits. This can be used to restore cortical activity that is altered in patients with CRPS (León et al., 2018).

Unlike other chronic pain conditions, the aim of CRPS treatment includes halting the progression of the disease early and thereby decreasing pain, rather than targeting pain alone. One approach is to reinforce afferent connections between the affected limb and the somatosensory cortex. In addition to pain, CRPS is associated with structural and functional changes of the somatosensory, primary motor, and supplementary motor areas (Urits et al., 2018; Echalier et al., 2020). Specifically, cortical representations of the affected limb in the somatosensory cortex are smaller and possess greater overlap with adjacent areas (Swart et al., 2009; Pietro et al., 2013). This is speculated to be a result of a decrease in afferent input originating from the periphery (Legrain et al., 2011; Moseley et al., 2012). Additionally, this reorganization is reinforced by the minimal usage of the affected limb by patients in order to avoid pain (Echalier et al., 2020). As such, this begins to raise the question, as to whether a sensorimotor task that stimulates afferent input originating from the periphery may aid in reinstating somatosensory cortical territory and ultimately aid in pain relief in these patients.

The objective of this study is to investigate the feasibility of the study procedures in a feasibility study involving 18 patients. In addition, the use of rTMS paired with a sensorimotor training task will be investigated in CRPS I patients, to induce positive neuroplastic changes so as to effect temporary and long-term pain relief. rTMS will be delivered to the primary motor cortex controlling the hand to create an environment within the sensory motor cortex that promotes neuroplasticity. This is accomplished through high frequency rTMS which increases cortical excitability (León et al., 2018). This in turn promotes intraneuronal connectivity and reorganization achieved through sensorimotor integration provided by the sensorimotor training task. In this task, digits two through five and the wrist on the affected hand will be non-invasively stimulated individually and require the participant to make a movement with that digit or wrist.

Study design: All participants will provide written informed consent. The patients will maintain their current medications and physiotherapy throughout the duration of the experiment. Participants will be randomly allocated into one of three groups. All groups will continue to have conservative care and physiotherapy as appropriate to their condition. Group A-control will not experience the intervention, group B will experience the rTMS and sensorimotor training intervention. Group C will experience the sensorimotor training intervention only. The intervention will be performed approximately 4 days per week for 4 weeks. During this 4 week time period, participants in group A will not experience any intervention.

Study intervention procedure: Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left motor cortex representation of the right abductor pollicis brevis (APB) muscle regardless of affected hand (Sun et al., 2019). Surface electromyography (EMG) electrodes will be placed on the skin overlying the APB muscle. The skin site will be cleaned using alcohol prior to adhering the disposable electrodes. Next the location of the right APB muscle in the left hemisphere will be determined by delivering stimuli at \~50 % maximum stimulator output (MSO) over the approximate location of the right APB representation and adjusting the coil position until large and consistent motor evoked potentials (MEPs) are elicited. If the investigators are unable to get a MEP from the APB muscle, the investigators will attempt to obtain the MEP from the first dorsal interosseous muscle. The spatial position that elicits large and consistent MEP's will be recorded using Brainsight Neuronavigation. This location is referred to as the motor hotspot and will be used throughout the intervention. This procedure will take \~15min to complete. rTMS stimulation will be applied to the identified motor hotspot at 80% resting motor threshold (RMT) (Sun et al., 2019). RMT will be performed each time rTMS is delivered and at T0, T1 and T2. To obtain RMT, the patient will receive single pulses of TMS to the APB hotspot. The RMT is defined as the minimum TMS intensity that evokes a motor response of 50 μV in 5 out of 10 consecutive trials when the APB muscle is at rest. This procedure will take \~5min to complete. Following calibration of the RMT, the patient will receive the rTMS stimulation using a 90 mm figure-8 coil. The coil will be positioned tangent with the scalp at 45° from midline, and the handle of coil will be pointed 5° backward and laterally. The patient will receive 2000 pulses at 10 Hz stimulation frequency (Sun et al., 2019; Yilmaz et al., 2014; Jette et al., 2013; Kang et al., 2009; Nardone et al., 2017). One hundred and sixty-seven trains will be delivered for a duration of 1.2s (3s inter-train interval) (Sun et al., 2019). rTMS delivery will require \~11.5 min to complete.

For participants in Group B, immediately following rTMS the participant will engage in a sensorimotor training task that involves digital and median nerve stimulation applied to each individual digit separately using ring electrodes and the median nerve using a bar electrode. Participants in group C will experience the sensorimotor training task without rTMS before hand. During the sensorimotor training task participants will experience nerve stimulation to either one of their digits (2-5) or the median nerve at the wrist. A trial will commence when one of the areas (digit or wrist) is stimulated for 2 ms with either one or two pulses of stimulation. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This training will require approximately 30 minutes.

Eligibility criteria: Inclusion Criteria:

* A diagnosis of CRPS type 1 affecting one of their hands

Exclusion Criteria:

* A known history of moderate to severe chronic pain in other parts of the body
* Daily use of opioids prior to the CRPS diagnosis
* Contraindications to transcranial magnetic stimulation
* Known psychological diagnosis affecting comprehension
* Inability to participate in the study

Primary outcomes:
measure: Ability to recruit 6 patients in each group over a 6-month period
timeFrame: Immediately following the 4 week intervention.
measure: Compliance of treatment sessions as proposed
timeFrame: Immediately following the 4 week intervention.
Secondary outcomes:
measure: Complex Regional Pain Syndrome Severity Scale
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: PROMIS-29 v2.0 Profile
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) Pain Score
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: The Rainbow Pain Scale
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Douleur Neuropathique 4 (DN4 Scale)
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Medication Use
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Patient Perceived Global Index of Change (PGIC)
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Assessments of swelling and skin discolouration using pictures and videos
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: The Patient Rated Wrist/Hand Evaluation (PRWHE scale)
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Sensory nerve action potentials
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Somatosensory evoked potentials
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Hoffman reflex
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Von Frey Filaments
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Johnson Vanboven Phillips Domes (JVP)
timeFrame: 1 week before intervention, immediately before intervention, immediately following intervention, 6 months after intervention
measure: Brain derived neurotrophic factor (BDNF)
timeFrame: Immediately before intervention, immediately following intervention
measure: Nerve growth factor (NGF)
timeFrame: Immediately before intervention, immediately following intervention
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare Hamilton King Campus
state: Ontario
Study officials:
References: